INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the ninth in women, with 554,000 and 228,000 new cases per year, respectively \[[@R1]\]. In addition, HCC is the second most common cause of death for cancer worldwide, estimated to be responsible for nearly 750,000 deaths per year, i.e., 9% of all cancer deaths \[[@R1]\]. Finally, HCC is the predominant type of primary liver cancer, arising mostly in cirrhotic livers \[[@R2]\].

The epidemiology of HCC reflects that of the etiological agents responsible for chronic liver diseases. In developing countries, liver cancer is strongly associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) chronic infection, liver cirrhosis being the morphologic substrate for HCC development in 80% of cases. In particular, HBV chronic infection accounts for approximately 50% of all cases and, virtually, of all HCC cases observed in childhood \[[@R3]\]. The progressive application of universal HBV vaccination of new-born babies has significantly reduced the incidence of HBV-related HCC in developed countries, a reduction strengthened by the increasing use in the last decade of drugs suppressing HBV chronic infection in nearly all patients treated. In addition, the increasing use in recent years of directly acting antiviral agents that induce HCV eradication in nearly 95% of patients with chronic hepatitis C will significantly reduce, although perhaps not fully eliminate, the risk of developing HCC \[[@R4]\]. At present, the epidemiology of HCC in developed countries shows a reduced impact of both HBV and HCV chronic infections and an increasing role of non-alcoholic fatty liver diseases (NAFLD) \[[@R5]\].

Although poorly explored at present, the large pool of individuals with occult HBV infection represents a further risk of HCC development. Occult HBV infection (OBI), defined as the presence of HBV DNA in liver tissue (regardless of its detectability in serum) of individuals testing negative for serum hepatitis B surface antigen (HBsAg) \[[@R6]\], is a relatively common condition in patients with circulating antibodies to the hepatitis B core antigen (anti-HBc) \[[@R7]\]. There is some evidence suggesting that the persistent synthesis of undetectable amounts of viral transcripts may induce an HBV-specific immune response with resulting liver necroinflammation \[[@R8], [@R9]\], but the role of OBI on the progression of liver damage remains unclear. Despite the biological, epidemiological and clinical evidence of the oncogenic potential of overt HBV infection, the role of OBI in the development of HCC is unclear \[[@R10]--[@R14]\]. The information on the mutations in the HBsAg region in patients with OBI and HCC are scanty and fragmentary and do not allow conclusions to be drawn on this point \[[@R15]--[@R16]\].

This study was performed to assess the epidemiological, virological and clinical characteristics of OBI in HBsAg-negative subjects with HCC and to investigate the relationship between HBsAg mutations and HCC.

PATIENTS AND METHODS {#s2}
====================

Patients {#s2_1}
--------

This study was planned as prospective with a progressive enrolment by the senior investigators of two participating Liver Units in Naples, southern Italy. All consecutive patients who underwent a diagnostic liver biopsy for HCC at one of the two participating liver units from June 2013 to December 2014 were enrolled. HCC was diagnosed in accordance with the EASL/EORTC criteria \[[@R17]\].

Each patient underwent a complete physical examination, full liver function tests and serology for HBsAg, anti-HCV and anti-HIV. HBsAg-positive and anti-HIV-positive patients were excluded from the study. The anti-HCV-positive subjects were considered as having HCV infection. A diagnosis of NAFLD and NASH (non-alcoholic steato-hepatitis) were made according to the AASLD/ACG/AGA guidelines \[[@R18]\]. Alcohol intake and other potential causes of liver disease were assessed. A consumption of alcohol exceeding 30g per day for females and 40g per day for males over at least the last 6 months (information corroborated by family members in uncertain cases) was considered alcohol abuse possibly speeding up the progression of the liver disease to an unfavorable outcome. By the end of the enrolment period, 68 consecutive HBsAg-negative/anti-HIV-negative patients with biopsy-proven HCC had been recruited and 12 excluded (9 because of HBsAg positivity, 2 because of anti-HIV positivity and 1 because of not availability of liver tissue).

The stage of HCC was assessed by the criteria proposed by the BCLC (Barcelona Clinic Liver Cancer) group \[[@R19]\].

For each patient, a non-HCC liver specimen and an HCC specimen were obtained by US-guided percutaneous liver biopsy. Fragments of nearly 3 mg were cut away from the two extremities of the liver biopsies, usually not informative for histological diagnosis, and stored at −80°C in RNAlater solution (Qiagen GmbH, Hilden, Germany) for subsequent molecular analyses. In addition, plasma samples were collected for each patient and stored at −80°C the same day the liver biopsies were performed.

All procedures followed were in accordance with the international guidelines and with the Helsinki Declaration of 1975, revised in 1983. The Ethics Committee of the Azienda Ospedaliera Universitaria of the Second University of Naples approved the study (n°349/2013). All patients signed their informed consent for liver biopsy, the collection and storage of biological samples and for the anonymous use of their data for research purposes.

Sero-virological methods {#s2_2}
------------------------

HBV serum markers (HBsAg, anti-HBs, anti-HBc) were sought using commercial immunoenzymatic assays (Abbott Laboratories, North Chicago, IL, USA). The anti-HCV antibody was sought using a 3rd generation commercial immunoenzymatic assay (Ortho Diagnostic Systems, Neckargemund, Germany). Antibodies to HIV 1 and 2 were sought using a commercial ELISA (Abbott Lab., North Chicago, IL, USA). Liver biochemistry and routine analyses were performed by routine methods in a Cobas Modular 6,000 automated analyzer using c501 biochemistry modules (Roche Diagnostics Ltd, Rotkreuz, Switzerland).

The fragments of liver tissue cut away from the liver biopsies were homogenized by TissueLyser (Qiagen GmbH, Hilden, Germany) for 30 seconds at 30 Hz and the DNA was extracted using microspin columns (QIAamp DNA kit, Qiagen GmbH). Plasma DNA was extracted from 200μl of plasma using microspin columns (QIAamp DNA Blood kit, Qiagen GmbH). The DNA extracted from plasma and from the homogenates of HCC and non-HCC liver tissues were analyzed for the presence of HBV DNA by three polymerase chain reactions (PCRs) using sets of primers for core, surface and x regions of the HBV genome, as previously reported \[[@R7]\]. For each compartment (plasma, HCC and non-HCC tissue), occult B infection was established by the presence of HBV DNA in at least two different PCR assays \[[@R6]\]. In subjects with OBI, the HBV genotype and the mutations in the HBV pre-S/S coding region were determined by automated sequencing, as previously described \[[@R20]\].

Specifically, HBV genotypes were determined by phylogenetic analysis of sequences of 500 nt of the S region by a nested PCR, using in the first PCR the outer primes F-2862 forward 5′-TCACCATATTCTTGGGAAC-3′ and R-853 5′-AGGGTTTAAATGTATAACCCA-3′, and in the second PCR the inner primers F-179 5′-CTAGGACCCCTGCTCGTGTT-3′ and R-690 reverse 5′-AATGGCACTAGTAAACTGAG -3′. The PCR products were then purified using the MinElute PCR Purification Kit (Qiagen, Qiagen GmbH); the sequencing reaction was performed using the primer forward F-179 5′-CTAGGACCCCTGCTCGTGTT-3′ and reverse R-690 5′-AATGGCACTAGTAAACTGAG-3′ with the Big Dye Terminator v 1.1 Cycle Sequencing Kit (Applied Biosystems, Carlsbad, CA, USA) in an ABI 310 Genetic Analyzer (Applied Biosystems). Sequences were aligned using the BioEdit program with reference sequences for the different genotypes deposited in GenBank (accession numbers: X02763, X51970, AF090842 for genotype A; D00329, AF100309, AB033554 for genotype B; X04615, M12906, AB014381 for genotype C; X65259, M32138, X85254 for genotype D; X75657, AB032431 for genotype E; X69798, AB036910, AF223965 for genotype F; AF160501, AB064310, AF405706 for genotype G; AY090454, AY090457, AY090460 for genotype H). Genetic distances were calculated with the Kimura-2-parameter algorithm and a neighbour-joining phylogenetic tree was constructed with the Mega 6 program <http://www.megasoftware.net> (Center of Evolutionary Functional Genomics, Biodesign Institute, Arizona State University, USA).

The pre-S /S coding region was amplified by nested PCR, using for the first PCR the primers F-2845 5′-CCTCATTTTGCGGGTCACC-3′ and R-996 5′-TTTGACCATACTTTCCAATCAAT-3 and for the second PCR primers F-2862 5′-TCACCATATTCTTGGGAAC-3′ and R-853 5′-AGGGTTTAAATGTATAACCCA-3′. The PCR products were then purified using the MinElute PCR Purification Kit (Qiagen, Qiagen GmbH) according to the manufacturer\'s instructions. Sequence reactions were performed with primers F-2862 and R-853 and the following primers: F-246 5′-GTCTAGACTCGTGGTGGACTT-3′, F-3037 5′-TTGGGGTGGAGCCCTCAGGCT-3′, F-56 5′-CCTGCTGGTGGCTCCAGTTCA-3′, R-690 5′-AATGGCACTAGTAAACTGAG-3′, using the Big Dye Terminator v 1.1 Cycle Sequencing Kit (Applied Biosystems, Carlsbad, CA, USA), according to the manufacturer\'s instructions, and run in an ABI 310 Genetic Analyzer (Applied Biosystems). The genotype was determined using the Genotyping Tool on <http://www.ncbi.nlm.nih.gov>

For anti-HCV positive patients, viral RNA was extracted from 140 μl of plasma samples using a microspin column (QIAamp RNA viral kit, Qiagen GmbH). HCV RNA was quantified by performing real-time PCR in a Light cycler 1.5 (Roche Diagnostics, Branchburg, NJ, USA), as reported in a previous paper \[[@R21]\]; by this method, the detection limit in plasma samples is estimated at around 40 IU/mL. HCV genotypes were determined by the HCV genotype Lipa assay (Bayer, France) following the manufacturer\'s instructions.

Statistical analysis {#s2_3}
--------------------

Continuous variables were summarized as mean and standard deviation, and categorical variables as absolute and relative frequencies. The differences were evaluated by Student\'s *t*-test for continuous variables, while categorical variables were compared by chi-square test, using exact procedures if necessary.

RESULTS {#s3}
=======

Characteristics of patients {#s3_1}
---------------------------

The demographic, clinical, biochemical and virological data of the 68 patients enrolled are summarized in Table [1](#T1){ref-type="table"}. Thirty-nine patients (57.3%) were males and the mean age was 70.2+6.24 years. All 68 patients had biopsy proven cirrhosis, 59 (85.3%) were HCV-related (38 with genotype 1) and the remaining 9 (14.7%) NASH-related. Of the 68 patients enrolled, 17 (25.0%) were anti-HBs/anti-HBc-positive, 11 (16.2%) anti-HBs-negative/anti-HBc-positive and 40 (58.8%) anti-HBc/anti-HBs-negative. Liver cirrhosis was in the Child-A stage in 58 (85.3%) patients and in the Child-B stage in 10 (14.7%). HCC was mono-focal in 38 (55.9%) patients and multifocal in 30 (44.1%); only two patients (2.9%) had portal thrombosis. It was first diagnosed at enrolment in 48 patients (70.6%) and as a relapsing HCC in the remaining 20 (29.4%), all previously treated with radiofrequency ablation; of these 20, 11 was mono-focal and 9 multifocal, one had portal thrombosis. Sixty-one (89.7%) patients presented a BCLC stage A, 6 (8.8%) a BCLC stage B and 1 (1.5%) C (Table [1](#T1){ref-type="table"}).

###### Demographic, biochemical, virological, and clinical characteristics of the patients enrolled

  -----------------------------------------------------------------
  N° patients                                    68
  ---------------------------------------------- ------------------
  Mean age (±SD)                                 70.2 (6.24)

  Males, n° (%)                                  39 (57.3)

  Alcohol abusers(\> 30g/die), n° (%)            2 (2.9)

  Subjects with diabetes, n° (%)                 8 (11.7)

  BMI (mean ± SD)                                27.1 (2.8)

  AST/ULN(mean ± SD)                             1.68 (0.9)

  ALT/ULN (mean ± SD)                            1.59 (0.8)

  ALP/ULN (mean ± SD)                            1.17 (0.5)

  Total bilirubin, mg/dl (mean ± SD)             1.53 (3.7)

  PT% (mean ± SD)                                84.7 (24.6)

  α−fetoprotein, (mean ± SD)                     173.7 (552.7)

  Anti-HCV-positive patients, n° (%)\            59 (86.8)\
  HCV-RNA-positive subjects, n° (%)\             47 (79.7)\
  HCV load, IU/mL (mean ± SD)\                   1.15E6 (1.78E6)\
  with HCV-genotype 1, n° (%)\                   38 (64.4)\
  with HCV-genotype non-1, n° (%)                9 (15.2)

  Patients with NASH, n°(%)                      9 (13.2)

  Child Pugh score, n° (%) of patients with\     58 (85.3)\
  A\                                             10 (14.7)\
  B\                                             0 (0)
  C                                              

  Patients with first diagnosis of HCC, n° (%)   48 (70.6)

  Patients with HCC relapse, n° (%)              20 (29.4)

  Patients with a single HCC, n° (%)             38 (55.9)

  Patients with multiple HCC, n° (%)             30 (44.1)

  Patients with portal thrombosis, n° (%)        2 (2.9)

  BCLC score, n° (%) of patients with\           61 (89.7)\
  A\                                             6 (8.8)\
  B\                                             1 (1.5)
  C                                              
  -----------------------------------------------------------------

Correlation between OBI and the characteristics of the patients {#s3_2}
---------------------------------------------------------------

OBI (presence of HBV DNA in at least two different PCR assays) was detected in both HCC tissue and non-HCC liver tissue of 3 (4.4%) patients and in the HCC tissue of 10 (14.7%), whereas no patient showed an OBI in plasma. The results of the 3 HBV PCRs in the 13 patients with OBI are shown in the [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. In particular, OBI was detected in 6 (54.5%) of the 11 anti-HBs-negative/anti-HBc-positive patients, in 5 (29.4%) of the 17 anti-HBs/anti-HBc-positive and in 2 (5%) of the 40 anti-HBs/anti-HBc-negative (*p* \< 0.0005 by Chi-square test of Pearson). Of the 3 patients with OBI in both HCC tissue and non-HCC liver tissue, two were anti-HBs-negative/anti-HBc-positive and 1 anti-HBs/anti-HBc-positive. The 13 patients with OBI in HCC tissue compared with the 55 without (Table [2](#T2){ref-type="table"}) were younger (65.7+8 years *vs*. 71.2+5.3, *p* = 0.03) and more frequently showed liver cirrhosis in the Child B stage (53.9% *vs*. 5.5%, *p* \< 0.0001) and a BCLC stage B or C (46.1% *vs*. 1.8%, *p* \< 0.0001) (Table [2](#T2){ref-type="table"}). No other significant difference was observed between these subgroups as regards the demographic, biochemical and clinical data such as unifocal/multifocal HCC, HCC first diagnosis/relapse and the presence/absence of portal thrombosis (Table [2](#T2){ref-type="table"}).

###### Demographic and initial biochemical, serological, virological and clinical data according to the presence of occult HBV infection in HCC tissue

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameters                                     Patients with occult HBV infection   Patients without occult HBV infection   *p*
  ---------------------------------------------- ------------------------------------ --------------------------------------- ------------------------------------------------
  N° of patients                                 13                                   55                                      

  Mean age (±SD)                                 65.7 (8.0)                           71.2 (5.3)                              0.03[\*](#tfn_001){ref-type="table-fn"}

  Males, n° (%)                                  7 (53.8)                             32 (58.2)                               0.78[\*\*](#tfn_002){ref-type="table-fn"}

  Alcohol abusers(\> 30g/die), n° (%)            1 (7.7)                              1 (1.8)                                 0.26[\*\*](#tfn_002){ref-type="table-fn"}

  Subjects with diabetes, n° (%)                 2 (15.4)                             6 (10.9)                                0.97[\*\*](#tfn_002){ref-type="table-fn"}

  BMI (mean ± SD)                                28.8 (3.5)                           26.6 (2.4)                              0.07[\*](#tfn_001){ref-type="table-fn"}

  AST/ULN(mean ± SD)                             1.85 (0.9)                           1.64 (0.9)                              0.52[\*](#tfn_001){ref-type="table-fn"}

  ALT/ULN (mean ± SD)                            1.78 (1.0)                           1.56 (0.8)                              0.51[\*](#tfn_001){ref-type="table-fn"}

  ALP/ULN (mean ± SD)                            1.38 (1.0)                           1.12 (0.4)                              0.41[\*](#tfn_001){ref-type="table-fn"}

  Total bilirubin, mg/dl (mean ± SD)             1.04 (0.5)                           1.63 (4.0)                              0.31[\*](#tfn_001){ref-type="table-fn"}

  PT% (mean ± SD)                                92.8 (11.6)                          83.1 (26.3)                             0.06[\*](#tfn_001){ref-type="table-fn"}

  αfetoprotein, (mean ± SD)                      97.5 (170.3)                         188.9 (601.1)                           0.39[\*](#tfn_001){ref-type="table-fn"}

  Anti-HCV-positive patients, n° (%)\            11 (84.6)\                           48 (85.4)\                              0.80[\*\*](#tfn_002){ref-type="table-fn"}\
  HCV-RNA-positive subjects, n° (%)\             9 (81.8)\                            38 (79.2)\                              0.99[\*\*](#tfn_002){ref-type="table-fn"}\
  HCV load, IU/mL (mean ± SD)\                   1.57E6 (2.48E6)\                     1.07E6 (1.64E6)\                        0.98\*\
  with HCV-genotype 1, n° (%)                    6 (54.5)                             32 (68.1)                               0.23[\*\*](#tfn_002){ref-type="table-fn"}

  Patients with NASH, n°(%)                      2 (15.4)                             7 (12.7)                                0.80[\*\*](#tfn_002){ref-type="table-fn"}

  Anti-HBs-negative/anti-HBc-positive, n° (%)\   6 (46.1)\                            5 (9.1)\                                Anti-HBc pos vs neg\
  Anti-HBs /anti-HBc-positive, n° (%)\           5 (38.5)\                            12 (21.8)\                              0.001[\*\*](#tfn_002){ref-type="table-fn"}
  Anti-HBs /anti-HBc-negative, n° (%)            2 (15.4)                             38 (69.1)                               

  Child Pugh score, n° (%): A\                   6 (46.1)\                            52 (94.5)\                              \<0.00001[\*\*](#tfn_002){ref-type="table-fn"}
  B                                              7 (53.9)                             3 (5.5)                                 

  Patients with first diagnosis of HCC, n° (%)   8 (61.5)                             40 (72.7)                               

  Patients with HCC relapse, n° (%)              5 (38.5)                             15 (27.3)                               0.45[\*\*](#tfn_002){ref-type="table-fn"}

  Patients with a single HCC, n° (%)             8 (61.5)                             30 (54.6)                               

  Patients with multiple HCC, n° (%)             5 (38.5)                             25 (45.4)                               0.61[\*\*](#tfn_002){ref-type="table-fn"}

  Patients with portal thrombosis, n° (%)        1 (7.7)                              1 (1.8)                                 0.26[\*\*](#tfn_002){ref-type="table-fn"}

  BCLC score, n° (%) of patients with\           7 (53.9)\                            54 (98.2)\                              Score A vs. B/C\
  Score A\                                       5 (38.5)\                            1 (1.8)\                                \<0.00001[\*\*](#tfn_002){ref-type="table-fn"}
  B\                                             1 (7.6)                              0                                       
  C                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Student\'s t-test;

chi-square test

HBV genotype and mutations in the S region in OBI {#s3_3}
-------------------------------------------------

Of the 13 patients with OBI, 12 had HBV-genotype D3 and one genotype A2.

The sequences of pre-S/S coding regions were found in the HCC tissue of 6 of the 13 patients with OBI, the HBV loads being too low for sequencing in the untested samples, and in all 3 with OBI in the non-HCC tissue.

### Mutations and deletions in the pre-S1, pre-S2 and S region in the HCC tissue {#s3_3_1}

Of the 6 patients for whom the pre-S/S region was sequenced in the HCC tissue, 5 showed amino acid (AA) mutations or deletions in pre-S1, pre-S2 and S regions, and one no AA mutation or deletion in all regions (Table [3](#T3){ref-type="table"}). More precisely, as regards the S region, 4 patients showed AA substitutions: Q129H in two patients, P24L in one and F19L, S59F and T131I in one (Table [3](#T3){ref-type="table"}). Regarding the pre-S1 region, 5 patients showed AA mutations (T40S in two patients, P124K in one, L54P and G76A in one, N222T and I273L in one) and 4 showed deletions(in positions 4, 8 and 17 in 3 patients and positions 8, 17 and 86 in one) (Table [3](#T3){ref-type="table"}). Finally, 4 patients showed an AA mutation in the pre-S2 region: P41H in 3 patients and P66L in one (Table [3](#T3){ref-type="table"}).

###### mutations in the pre-S1, pre-S2 and S regions in HCC and non-HCC liver tissue

  Patient        HCC tissue          Non-HCC liver tissue                                                                                                                              
  -------------- ------------------- --------------------------------------------- -------------- -------------- --------------------------------------------------------------------- ---------------------------------------------------
  Patient \#1    No mutations        L54P, G76A, AA deletion in positions 4,8,17   P41H           G44G/E I92T    G91A, I255T                                                           G99E, I147T
  Patient \#2    P24L                N222T, I273L                                  P66L           PCR negative   PCR negative                                                          PCR negative
  Patient \#3    F19L, S59F, T131I   P124K, AA deletion in positions 4,8,17        P41H           PCR negative   PCR negative                                                          PCR negative
  Patient \#4    Q129H               T40S, AA deletion in positions 4,8,17         No mutations   Q129H          S98T, N103D, T114I, T119P, AA deletion in positions 128,129,130,131   F75S, Q184H, AA deletion in positions 19,20,21,22
  Patient \#5    Q129H               T40S AA deletion in positions 8,17,86         P41H           PCR negative   PCR negative                                                          PCR negative
  Patient \# 6   No mutations        No mutations                                  No mutations   N59T, I110L    No mutations                                                          H114T, I165L

Thus, the mutations most frequently observed in these 6 patients were AA substitutions Q129H in the S region (2 of 6 patients), T40S in the pre-S1 (2 of 6 patients) and P41H in the pre-S2 region (4 of 6 patients) and deletions in positions 8 and 17 in the pre-S1 region (4 of 6 patients), associated with a deletion in position 4 in 3 cases and in position 86 in one.

### Mutations and deletions in the pre-S1, pre-S2 and S region in non-HCC liver tissue {#s3_3_2}

The pre-S1, pre-S2 and S regions were sequenced in the non-HCC liver tissue of all 3 patients with OBI in the non-HCC tissue. The following AA substitutions and deletions were observed: a) G44E, I92T, Q129H, N59T, and I110L AA substitutions in the S region; b) AA deletions in position 128-131 and G91A, I255T, S98T, N310D, T114I, and T119P AA substitutions in the pre-S1 region; c) AA deletions in position 19-22 and G99E, I147T, F75S, Q184H, H114T and I165L AA substitutions in the pre-S2 region (Table [3](#T3){ref-type="table"}).

### Differences in mutations and deletions in the pre-S1, pre-S2 and S region between HCC and non-HCC liver tissue {#s3_3_3}

The sequencing of the S, pre-S1 and pre-S2 region of the 3 patients with OBI in HCC and in non-HCC liver tissue was compared to identify differences in the mutations and deletions.

In patient n°1 the AA substitutions and deletions differed widely between HCC and non-HCC liver tissue in the pre-S1, pre-S2, and S regions. In this patient, the HCC tissue showed no mutation in the S region, AA substitutions L54P and G76A and AA deletions in positions 4, 8 and 17 in the pre-S1 region and AA substitution P41H in the pre-S2 region, whereas the non-HCC liver tissue showed the G44G/E and I92T AA substitutions in the S region, G91A and I255T AA substitutions in the pre-S1 region and AA substitutions G99E and I147T in the pre-S2 regions.

In patient n°4, apart from the AA substitution Q129H in the S region in both tissues, sequencing in HCC and non-HCC liver tissue showed differences in the AA substitutions and deletions both in the pre-S1 region (T40S and AA deletion in positions 4, 8 and 17 for HCC and S98T, N103D, T114I, T119P and the AA deletion in position 128-131 for non-HCC liver tissue) and in the pre-S2 region (no AA substitution or deletion in HCC tissue and the AA substitutions F75S and Q184H and AA deletion in position 19-22 in the non-HCC liver tissue).

In patient n°6 no mutation was observed in the pre-S1, pre-S2 and S regions in the HCC tissue, whereas in the non-HCC liver tissue the N59T and I110L AA substitutions were observed in the S region, no mutation in the pre-S1 region and the AA substitutions H114T and I165L in the pre-S2 region.

DISCUSSION {#s4}
==========

An OBI-defining condition was observed in HCC tissue of nearly 20% of the 68 HBsAg-negative patients investigated in this study and more precisely in half of those with circulating anti-HBc alone, in nearly one-third of the anti-HBs/anti-HBc-positive and in only 5% of the anti-HBc-negative. Instead, only 3 of the 13 patients with an OBI-defining condition in HCC tissue showed OBI also in cirrhotic tissue. Taken together, these observations might support the hypothesis that OBI favours HCC development in HBsAg-negative cirrhotic patients, but the possibility that an OBI-defining condition may persist longer in HCC than in cirrhotic tissue cannot be ruled out. Moreover, although significantly younger, the subjects with OBI showed a more advanced clinical condition, expressed for liver cirrhosis by a more severe Child-Pugh score and for HCC by a worse BCLC score. The possibility that OBI may speed the progression of HCV-related liver diseases to a more severe stage has been suggested in some previous papers \[[@R22], [@R23], [@R24]\] that demonstrated that patients with HCV-related cirrhosis showed a higher rate of both HCC and liver-related events (development or bleeding of oesophageal varices, encephalopathy or ascites) if carrying OBI \[[@R22]\]. The mechanism by which OBI may enhance liver damage and induce HCC is still unclear, but a pathogenetic role of this occult infection cannot be excluded, since HBV is an oncogenic virus whose replication may induce liver cell proliferation, hepatocyte necrosis and neo-fibrogenesis \[[@R25]\].

The other aim of our study was to investigate the virological characteristics of occult B infection, particularly the presence of mutations in the pre-S1, pre-S2 and S regions of HBV, both in HCC and in non-HCC tissue. Some studies on HBsAg-positive Asian populations \[[@R26]--[@R28]\] have shown a relationship between deletions in the pre-S region and the development of HCC. These variants may have a reduced antigenicity and, by altering the immune response, may favour the replicative activity of the virus \[[@R29]\]. In addition, by decreasing the expression of middle and small surface proteins, the pre-S deletions may result in an intracellular accumulation of viral particles that may induce stress in the endoplasmic reticulum, oxidative DNA damage and genomic instability possibly leading to a neoplastic transformation \[[@R30]\]. No datum on a possible correlation between pre-S deletions in OBI and HCC development has so far been published, and the data of the present study are the first to demonstrate AA deletions in the pre-S1 region in HCC tissue. These deletions were found in positions 4, 8 and 17 in three of the 6 patients investigated and in positions 8, 17 and 86 in a fourth patient. Despite the low number of patients investigated, the data are interesting and warrant confirmation in further studies.

Also poorly investigated is the clinical value of point mutations in the pre-S1, pre-S2 and S regions in HBsAg-positive chronic hepatitis and even less in those with OBI. A case-control study \[[@R31]\] recently performed in Hong Kong on 74 HBsAg-positive subjects with HCC and 148 with chronic hepatitis B used as controls showed a significantly higher frequency of a AA substitutions in position 54 of the pre-S1 region in patients with HCC. In accordance with this, we found an L54P AA mutation in the pre-S1 region in the HCC liver tissue of one of the 3 patients with OBI investigated for both HCC tissue and non-HCC liver tissue.

In 2007, Pollicino and co-workers \[[@R15]\] identified a mutation in position 41 of the pre-S2 region in HCC tissue in 3 of 17 patients investigated, of whom two were HBsAg-positive and one showed OBI. Again as regards the pre-S2 region in OBI, we detected the mutation P41H in the HCC tissue of 3 of the 6 patients with OBI investigated in the present study.

As regards the S region in OBI, we found the Q129H mutation in two HCC tissues and in one non-neoplastic liver tissue, a mutation located within the "a" determinant of HBsAg, already described as an escape mutation \[[@R32]\] but never associated with hepatic carcinogenesis.

Other AA deletions or substitutions presented in Table [3](#T3){ref-type="table"} have not been discussed here only because first described in the present study. Their clinical importance, however, cannot be excluded, but further investigations are needed for a more comprehensive discussion.

In conclusion, we found a significant correlation between the presence of OBI and the severity of liver damage in the 68 HBsAg-negative patients with liver cirrhosis and hepatocellular carcinoma investigated. Different patterns of mutations in the S, pre-S1 and pre-S2 regions were observed in the HCC tissue and non-HCC liver tissue. Several AA deletions and AA substitutions were observed, some previously deemed as possibly associated with HCC development and others described for the first time in the present study. Although the small number of patients with OBI investigated in the present study and the scanty, fragmentary data reported in the literature make it difficult to draw conclusions, the data from the present study seem interesting and might constitute cornerstones for future scientific developments.

SUPPLEMENTARY TABLE {#s5}
===================
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HBV

:   hepatitis B virus

HCC

:   hepatocellular carcinoma

OBI

:   occult HBV infection

NAFLD

:   non alcoholic fatty liver diseases

HBsAg

:   hepatitis B surface antigen

anti-HBc

:   antibody to hepatitis B core antigen
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:   Barcelona clinic liver cancer
